Upamostat - RedHill Biopharma

Drug Profile

Upamostat - RedHill Biopharma

Alternative Names: Mesupron; RHB-107; WX-671

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wilex
  • Developer Heidelberg Pharma AG; RedHill Biopharma; WILEX AG
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Pancreatic cancer
  • Clinical Phase Unknown Cancer; Gastrointestinal disorders
  • Discontinued Head and neck cancer

Most Recent Events

  • 01 Aug 2018 Clinical trials in Gastrointestinal disorders (PO) (RedHill Biopharma pipeline, August 2018)
  • 20 Oct 2017 Upamostat receives Orphan Drug status for Pancreatic cancer (Adjuvant therapy) in USA
  • 18 Sep 2017 Clinical trials in Cancer (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top